STAAR Surgical Company
Financials
Valuation Metrics
STAAR Surgical Company's Market Cap is $1.21B. At end of 2025 it was $1.14B. Ranked #2397 of 3,112 in US market (top 77%), #965 of 1,445 on NASDAQ (top 67%), #148 of 206 in Health Care Equipment & Services (top 72%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.21B | US#2,397/3,112 Sec#148/206 |
| Revenue | $290M | US#2,571/3,112 Sec#163/206 |
| Net Income | $-21M | US—/3,112 Sec—/206 |
| Total Assets | $451M | US#2,783/3,112 Sec#162/206 |
| Net Assets | $352M | US#2,468/3,112 Sec#136/206 |
| Employees | 921 | US#1,268/3,112 Sec#102/206 |
| Value | ||
| P/B | 3.44x | US#1,826/3,112 Sec#111/206 |
| P/S | 4.17x | US#2,115/3,112 Sec#147/206 |
| FCF Yield | -4.54% | US—/3,112 Sec—/206 |
| Profitability | ||
| ROE | -5.97% | US#2,332/3,112 Sec#127/206 |
| ROA | -4.66% | US#2,511/3,112 Sec#139/206 |
| Op. Margin | -1.72% | US#2,476/3,112 Sec#135/206 |
| Revenue Growth | 119.59% | US#113/3,112 Sec#2/206 |
| Financial Health | ||
| Debt Ratio | 28.03% | US#301/3,112 Sec#33/206 |
| Total Debt | $37M | US#2,601/3,112 Sec#156/206 |
| FCF | $-55M | US#2,477/3,112 Sec#181/206 |
| Cash | $132M | US#2,031/3,112 Sec#129/206 |
| Current Ratio | 5.12x | US#457/3,112 Sec#41/206 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,112 Sec—/206 |
| Payout Ratio | 0.00% | US—/3,112 Sec—/206 |
| Performance | ||
| 1Y Return | 37.05% | US#1,161/3,112 Sec#73/206 |
| 1M Return | -12.41% | US#2,711/3,112 Sec#177/206 |
| From 52W High | -32.14% | US#2,257/3,112 Sec#155/206 |
| 1Y MDD | -43.65% | US#2,141/3,112 Sec#120/206 |
| Trading | ||
| Volume | 1,043,707 shares | US#1,431/3,112 Sec#101/206 |
| Trading Value | $26M | US#1,830/3,112 Sec#122/206 |
| Per Share | ||
| EPS | $-1.96 | US—/3,112 Sec—/206 |
| BPS | $6.97 | US#2,047/3,112 Sec#124/206 |
Company Info
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.